



CONTACT: Lisa Walters-Hoffert, Executive Vice President and Chief Financial Officer  
Manda Hall, Investor Relations Administrator  
Cypress Bioscience, Inc.  
(858) 452-2323

## **Cypress Bioscience Advances FMS Initiative with the Launch of The Fibromyalgia Resource Center and On-line Patient Registry**

SAN DIEGO, CA – January 29, 2002 – Cypress Bioscience, Inc. (NASDAQ:CYPB) announced the launch of the Fibromyalgia Resource Center at [www.FMSresource.com](http://www.FMSresource.com) to provide patients, care providers and researchers with comprehensive information about Fibromyalgia Syndrome (FMS) and related conditions. A key contributor to the website is Georgetown University's renowned Chronic Pain and Fatigue Research Center.

The Fibromyalgia Resource Center provides visitors with information about FMS and illness management, FMS related news, a directory of doctors that are actively involved in the treatment of FMS, and a list of on-going clinical trials in chronic pain, FMS and related conditions. The website also features a first-of-its-kind, comprehensive on-line registry for FMS patients. By contributing the details of their condition and treatment histories through a confidential, web-enabled questionnaire, patients can help further the understanding of FMS.

The FMS Patient Registry is one of several initiatives undertaken by Cypress to gather well-characterized information on this large patient population. The Company's FMS Genomics Program involves collecting phenotypic profiles and blood samples from FMS patients. Patients participating in the Genomics Program complete the same web-enabled questionnaire available on [www.FMSresource.com](http://www.FMSresource.com) and provide a blood sample to their doctor. Cypress seeks to create a comprehensive 10,000-patient database for genomic analysis to support its broader research efforts in FMS.

“Published studies have shown that patients with FMS and other forms of chronic pain may have a genetic predisposition for the condition. The ability to analyze patients medical and treatment histories in combination with their genetic samples should enable us to better understand the origins and symptoms of this chronic condition so that promising treatment alternatives can be identified,” said Dr. Jay D. Kranzler, M.D., Ph.D., Chairman and CEO of Cypress Bioscience.

FMS is a chronic and debilitating condition characterized by widespread pain and stiffness throughout the body, accompanied by severe fatigue and headache. It affects an estimated 2%-4% of the population worldwide and is the second most common diagnosis by rheumatologists in the U.S. after osteoarthritis. Despite the high prevalence and severity of this syndrome, today there are no approved treatments specifically for FMS.

*(more)*

“Cypress aims to remain at the forefront of ongoing FMS research and drug development,” said Dr. Kranzler. “The ability to gather and analyze patient profiles and genetic samples will help us achieve these goals.”

### **About Cypress Bioscience, Inc.**

Cypress is committed to be the innovator and commercial leader in providing products that improve the diagnosis and treatment of patients with FMS. In January 2001, the Company began a strategic initiative focusing on FMS. In August 2001, Cypress licensed its first product for clinical development, milnacipran, to treat the widespread pain associated with FMS. In January of 2002, the Company’s IND was opened to commence a Phase II clinical trial to treat FMS with milnacipran in the United States. For more information about Cypress, please visit the Company's web site at [www.cypressbio.com](http://www.cypressbio.com).

*This press release, as well as Cypress' SEC filings and web site at <http://www.cypressbio.com>, contain forward-looking statements, including among others, statements regarding the Company's continued listing of the Company's securities on The Nasdaq SmallCap Market, within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could vary materially from those described as a result of a number of factors, including those set forth in Cypress Annual Report on Form 10-K and any subsequent SEC filings. In addition, there is the risk that we may not be able to successfully develop or market any products for the treatment of FMS under the Pierre Fabre agreement or at all; that our clinical development plan or timeline for milnacipran may be delayed, including our plan to begin treating patients in a Phase II clinical trial in early 2002; that we may encounter regulatory or other difficulties in the development of milnacipran for FMS; and that milnacipran may not significantly improve the treatment of FMS. Cypress undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.*

# # #